Meeting
2019 ASCO Annual Meeting
Development and validation of a prognostic score for overall survival integrating baseline metabolically active tumor volume measured by 18F-FDG PET/CT and clinical factors for metastatic colorectal cancer patients.
Authors
Erwin Woff
Nuclear Medicine Department, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium
Erwin Woff , Alain Hendlisz , Lisa Salvatore , Federica Marmorino , Alfredo Falcone , Dario Genovesi , Assuero Giorgetti , Gabriela Critchi , Lieveke Ameye , Marianne Paesmans , Thomas Guiot , Hugo Levillain , Patrick Flamen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3543)
DOI
10.1200/JCO.2019.37.15_suppl.3543
Abstract #
3543
Poster Bd #
35
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Association of body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) who received targeted therapies (TT).
First Author: Gargi Surendra Patel
Poster
2022 ASCO Annual Meeting
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC).
First Author: Hiroyuki Arai
Poster
2017 ASCO Annual Meeting
Baseline cell-free DNA (cfDNA) and metabolic tumor volume (MTV) independently predict outcome in metastatic chemorefractory colorectal cancer (mCRC).
First Author: Erwin Woff
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world comparison of low- versus high-dose continuous 5FU infusion in patients receiving triplet chemotherapy plus bevacizumab for newly diagnosed metastatic colorectal cancer (mCRC).
First Author: William Joseph Chapin